Lannett Co Inc (LCI) 40.77 $LCI Valeant (VRX) in Focus

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Lannett Co Inc (LCI) 40.77 $LCI

Valeant (VRX) in Focus on Intensifying Government Probe
Zacks Equity Research - Zacks Investment Research - Fri Oct 16, 1:20PM CDT
Valeant (VRX) has hit a rough patch ever since concerns arose about the irrational increase in drug prices by U.S. pharma/biotech companies.
LCI: 40.77 (-0.38), VRX: 98.32 (-20.29), ANAC: 92.60 (-1.13)

Prothena to Start Phase IIb Study on AL Amyloidosis Drug
Zacks Equity Research - Zacks Investment Research - Fri Oct 16, 1:10PM CDT
Prothena (PRTA) announced that it will commence a phase IIb study on NEOD001 for patients suffering from AL amyloidosis and persistent cardiac dysfunction.
LCI: 40.77 (-0.38), ANAC: 92.60 (-1.13), PRTA: 46.90 (-0.33)

How Valeant is changing the Pharmaceutical Industry?
Zacks Equity Research - Zacks Investment Research - Thu Oct 15, 3:50PM CDT
It is still early to say if Valeant's (VRX) strategic plan will affect the general behavior of companies operating in the pharmaceutical sector.
IPXL: 33.90 (-1.11), LCI: 40.77 (-0.38), ENDP: 50.29 (-4.17), VRX: 98.32 (-20.29)

Lannett passes US FDA approval for Memantine Hydrochloride Oral Solution, 2 mg/ml to treat dementia associated with Alzheimer's disease
M2 - Thu Oct 15, 3:06AM CDT
Pharmaceutical products business Lannett Company (NYSE:LCI) revealed on Wednesday the receipt of approval from the US Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Memantine Hydrochloride Oral Solution 2 mg/ml.
LCI: 40.77 (-0.38)

Shire's Cinryze Gets Fast Track Status for Additional Indication
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 2:45PM CDT
Shire announced that its HAE drug Cinryze has been granted Fast Track designation for antibody mediated rejection (AMR) in renal transplant recipients by the FDA.
LCI: 40.77 (-0.38), SHPG: 205.10 (-1.57), AZN: 31.00 (+0.53)

Lannett Receives FDA Approval For Memantine Hydrochloride Oral Solution, 2 mg/mL
PR Newswire - Wed Oct 14, 5:53AM CDT
Lannett Company, Inc. (NYSE: LCI) today announced that its wholly owned subsidiary, Silarx Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Memantine Hydrochloride Oral Solution 2 mg/mL, the therapeutic equivalent to the reference listed drug Namenda® Oral Solution, 2 mg/mL of Forest Pharmaceuticals. According to IMS, for the year ended June 2015 total sales of Memantine Hydrochloride Oral Solution 2 mg/mL at Average Wholesale Price (AWP) were approximately $12 million.
LCI: 40.77 (-0.38)

Zacks Investment Ideas feature highlights: American Woodmark, Footlocker, Lannett, Ryanair Holdings and Carrols
Zacks Equity Research - Zacks Investment Research - Tue Oct 13, 8:30AM CDT
Zacks Investment Ideas feature highlights: American Woodmark, Footlocker, Lannett, Ryanair Holdings and Carrols
LCI: 40.77 (-0.38), RYAAY: 79.22 (-0.21), FL: 69.85 (-0.33), TAST: 12.29 (-0.05), AMWD: 70.87 (+1.88)

Zafgen (ZFGN) in Focus: Stock Plunges 35.6%
Zacks Equity Research - Zacks Investment Research - Tue Oct 13, 7:32AM CDT
Zafgen (ZFGN) fell nearly 36% in the last trading session amid huge volumes, continuing its recent trend, as the stock is now down over 44% in the past one month.
ZFGN: 11.00 (+0.28), LCI: 40.77 (-0.38)

5 Best Under the Radar Stocks
Tracey Ryniec - ZACKS - Mon Oct 12, 1:02PM CDT
5 Best Under the Radar Stocks
LCI: 40.77 (-0.38), RYAAY: 79.22 (-0.21), FL: 69.85 (-0.33), AMWD: 70.87 (+1.88), TAST: 12.29 (-0.05)

The Zacks Analyst Blog Highlights: Delta Air Lines, Tyson Foods, United Continental Holdings, Ally Financial and Lannett Company
Zacks Equity Research - Zacks Investment Research - Fri Oct 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Delta Air Lines, Tyson Foods, United Continental Holdings, Ally Financial and Lannett Company
LCI: 40.77 (-0.38), ALLY: 20.13 (-0.08), DAL: 50.81 (+1.37), TSN: 46.82 (+0.59), UAL: 55.75 (+1.20)

5 Value Stocks That Brokers Love
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 8:40AM CDT
Only a fundamentally strong company has the calibre to achieve its growth potential despite an unsupportive economic background. One such foolproof approach is investing in undervalued stocks that more than 80% brokers recommend.
LCI: 40.77 (-0.38), ALLY: 20.13 (-0.08), DAL: 50.81 (+1.37), TSN: 46.82 (+0.59), UAL: 55.75 (+1.20)

Why Valeant's (VRX) Shares Plummeted in Monday Trading
Zacks Equity Research - Zacks Investment Research - Tue Sep 29, 3:41PM CDT
Valeant (VRX) is one of the hardest hit stocks following Hillary Clinton's tweet on "price gouging." The company saw its shares plummet 16.5% yesterday.
ACRX: 3.21 (-0.10), LCI: 40.77 (-0.38), VRX: 98.12 (-20.49), CORT: 3.58 (-0.08)

Jazz Pharmaceuticals (JAZZ) Crumbles: Stock Falls by 7.7%
Zacks Equity Research - Zacks Investment Research - Tue Sep 29, 7:42AM CDT
Jazz Pharmaceuticals saw a big move last session, as the company's shares fell nearly 8% on the last trading day
LCI: 40.77 (-0.38), JAZZ: 120.03 (-1.91)

Pacira Pharmaceuticals (PCRX) Crumbles: Stock Falls by 7.7%
Zacks Equity Research - Zacks Investment Research - Thu Sep 24, 7:34AM CDT
Pacira Pharmaceuticals (PCRX) fell nearly 8% in the last trading session amid huge volumes, continuing its recent trend, as the stock is down nearly 18% since Sep 17.
LCI: 40.77 (-0.38), PCRX: 38.26 (-1.17)

Oil, Metals Prices Hurt Stocks; Car Makers, Miners, Biotechs Sacked
at Investor's Business Daily - Tue Sep 22, 9:46AM CDT
Sellers owned the early show on Tuesday, with stocks opening to losses that were broad and deep. The Nasdaq quickly slumped 1.5%. The Dow Jones industrial average and the S&P 500 each dropped 1.3%. Volume was tightly mixed, up 8% on the NYSE and 3%...
SPLS: 12.70 (+0.12), VRX: 98.12 (-20.49), F: 15.62 (+0.21), UTX: 100.10 (+2.13), FCAU: 15.33 (+0.13), NTAP: 34.33 (+0.93), TTM: 29.17 (+0.39), KMX: 58.62 (+1.32), LCI: 40.77 (-0.38), AZO: 759.88 (+14.59), GM: 35.45 (+0.03), MCD: 110.29 (+7.75)

McKesson to Buy UDG Healthcare's Pharmaceutical Business
Zacks Equity Research - Zacks Investment Research - Mon Sep 21, 2:55PM CDT
McKesson Corporation (MCK) signed an agreement to purchase UDG Healthcare's pharmaceutical distribution division for 408 million euro in cash.
LCI: 40.77 (-0.38), MCK: 180.63 (-5.99), ADHD: 6.32 (-0.17)

Major Indexes Still Mixed; Red Hat Up Ahead Of Earnings
at Investor's Business Daily - Mon Sep 21, 1:52PM CDT
Stocks have come off their session lows, but were still mixed late Monday. The Nasdaq cut a 0.6% deficit to 0.2%. But the tech-laden index was up as much as 1.1% intraday. The S&P 500 edged up 0.2% while the Dow Jones industrial average outperformed...
AGN: 253.70 (-5.30), LCI: 40.77 (-0.38), VRX: 98.12 (-20.49), CYBR: 47.56 (+1.15), RHT: 77.69 (+0.88), ILMN: 140.22 (+0.05), REGN: 519.54 (+1.01)

3 Reasons Why Lannett Company (LCI) is a Great Value Stock
Zacks Equity Research - Zacks Investment Research - Fri Sep 18, 7:52AM CDT
Lannett Company is a solid value stock that is very well-positioned for gains in the near term
LCI: 40.77 (-0.38)

'Mad Money' Lightning Round: Buy, Buy, Buy Amazing Starbucks
at The Street - Thu Sep 17, 5:00AM CDT
Cramer prefers Wells Fargo over HSBC Holdings and Kroger over Whole Foods Markets.
WFM: 32.93 (-0.05), SBUX: 61.55 (+1.02), LCI: 40.77 (-0.38), KR: 38.32 (+0.24), HSBC: 39.33 (+0.40), WFC: 54.42 (+1.30)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Joshua Davenport: Celebrating 25 Years in Healthcare

Updated Category News Views 1

25 Years Strong: Davenport's Journey in Healthcare Not every day you celebrate someone who's spent a quarter of a century in the trenches of healthcare. Joshua L. Davenport, RN, isn't just clocking years; he's built a legacy in emergency nursing and occupational health that speaks volumes about resilience and commitment to others. From Humble Beginnings to Health...

Continue Reading
Denarius Metals Unveils Technical Insight for Toral Project

Updated Category News Views 2

Denarius Metals Shares Tech Report on Toral Project It's a curious moment in the mining world when Denarius Metals decides to drop their latest gem—a technical report on the Toral Project. We're talking about a full-bodied document rooted in the stringent National Instrument 43-101 standards. This isn't some half-baked release; it's a robust assertion of where they...

Continue Reading
Hi3D Unlocks AI 3D Model for Open-Source Innovation

Updated Category News Views 6

A New Era in 3D Model Accessibility Unless you’ve been hiding under a rock, it’s hard to miss how digital terraforming has shifted gears. With Hi3D V1.0 opening its doors, the playing field's getting a major reshuffle. Or, as they say, the table is being set, and everyone's getting a seat. By letting loose production-validated AI tools, Hi3D is throwing down the...

Continue Reading
Better Home & Finance Faces Class Action: What's Next?

Updated Category News Views 3

Stock Hit and Legal Drama Panic set in when Better Home & Finance Holding Company took a 28.5% nosedive after spilling some less-than-sweet news. Their promise of hitting a billion in monthly loans? Stuck in limbo as borrower trepidation reared its ugly head amidst rising rates. Investors felt the heat, watching shares skydive $12.17, landing them at a bruised $30.52. A...

Continue Reading
FOX News Revamps 2026 Election Coverage Playbook

Updated Category News Views 2

Revamped Coverage: More Than Just Breaking News Yeah, everyone's clamoring about the midterms, but Fox News is doing more than just flipping on the camera and breaking the news every few minutes this year. They're rolling out the big guns: AI chatbots, flashy graphics, and special shows across multiple platforms. The point? To get viewers practically hooked and give 'em...

Continue Reading
Anavex Faces Securities Lawsuit: Investor Implications

Updated Category News Views 4

Storm Clouds Over Anavex: What Investors Need to Know If you've got a slice of Anavex Life Sciences Corp. (NASDAQ: AVXL) in your portfolio, the latest chapter of their legal saga feels less like a twist and more like a twist of the knife. These lawsuits often come out of left field for investors, but this one seems like a slow train that’s been gathering steam for a...

Continue Reading
Dimora Medical Boosts Advanced Wound Care at HS Conference

Updated Category News Views 3

Empowering the HS Community with Innovations Look, if you’ve walked a mile in someone else's shoes—particularly ones dealing with hidradenitis suppurativa (HS)—you’d know what a relentless grind managing those exuding wounds can be. Dimora Medical, known for navigating the tricky territory of wound care, threw its hat into the ring at the HS Connect Empower...

Continue Reading
Disorderly Magic: New Lithium Batteries Breakthrough

Updated Category News Views 4

Disorder in Structure: A Game-Changer? Lithium-ion batteries—yeah, the gizmos powering your fancy electric cars and gadgets—might have just hit their next big break, all thanks to a little chaos. Over in Chungcheong Province, South Korea, researchers at Hanbat National University are messing with the atomic structure of lithium-rich cathodes, and guess what? They're...

Continue Reading
MATIC S68 Wheels: A Bold Step for Superteam

Updated Category News Views 6

Premium Racing Takes a New Spin Scratch the surface of a tire-obsessed market, and you'll find Superteam Wheels making a calculated leap. Their new premium sub-brand, MATIC, isn't just fluff—it shows a serious attempt to impress those who’d rather cut corners on a track than a spreadsheet. Introducing the MATIC S68—buttery smooth, pitch-perfect, and undeniably...

Continue Reading
Lincoln Educational Faces Investor Lawsuit Over Revenue Drop

Updated Category News Views 3

Investors Face Rough Waters Okay, let’s dive into this latest mess at Lincoln Educational Services Corp. (NASDAQ:LINC). Things aren't smelling too rosy over at their headquarters. If you've got shares here, you’ll know what I mean. Back in early May, the folks running Lincoln threw a garden party talking up a 19.5% growth in student starts. Who wouldn’t get behind...

Continue Reading

Top 5 Most Recently Viewed Articles

M7 World Championship 2025: A New Era for Esports in Indonesia

Updated Category News Views 153

M7 World Championship 2025: A New Era for Esports in Indonesia The stage is set for the M7 World Championship—a monumental event poised to showcase Indonesia as a hub for global esports. This year, the championship promises to amplify the excitement surrounding Mobile Legends: Bang Bang (MLBB) Esports through a series of thrilling matches and vibrant cultural...

Continue Reading
James Hardie Industries Faces Class Action – Key Details Inside

Updated Category News Views 142

James Hardie Industries plc. Class Action Lawsuit Overview Investors in James Hardie Industries plc. (NYSE: JHX) are being alerted to an important class action lawsuit that is currently underway. This lawsuit aims to address concerns over alleged securities fraud that impacted shareholders. Understanding the Class Action Details The lawsuit's objective is to seek...

Continue Reading
Embla Medical Reports Impressive Growth in Q3 2024 Results

Updated Category News Views 152

Embla Medical Delivers Strong Q3 2024 Performance Sveinn Sölvason, President and CEO of Embla Medical hf, has shared positive updates regarding the company’s performance in the third quarter of 2024. With an impressive sales figure of USD 214 million, the company has demonstrated consistent organic growth of 7% compared to the same quarter in the previous year. Sales...

Continue Reading
Standex Invites Investors to Discuss Q1 Fiscal 2025 Updates

Updated Category News Views 188

Standex International Corporation Announces Investor Call Standex International Corporation (NYSE: SXI) has officially scheduled an important investors' conference call to discuss its first quarter fiscal 2025 financial results. This call is set for the morning and will also cover the recent acquisition of Amran Instrument Transformers and Narayan Powertech Pvt. Ltd....

Continue Reading
Douglas Elliman Welcomes New Executive: Key Financial Insights

Updated Category News Views 274

Douglas Elliman's New Appointment and Its Implications Douglas Elliman Inc. (NYSE:DOUG), a leading real estate agency, has officially announced a significant change in its executive team. This change comes as the company moves forward with a fresh strategy aimed at enhancing its market position. James Bryant Kirkland III has been appointed as the Executive Vice President,...

Continue Reading